Biontech SE expected to post earnings of 79 cents a share - Earnings Preview

What happened

BioNTech SE is expected to report a 30.6% fall in quarterly revenue to €1.055 billion from €1.52 billion a year ago, according to the average estimate of 11 analysts using LSEG data, when it reports results on November 3 for the quarter ending September 30, 2026.

Confirmed

Global impact / market context

A sharp revenue drop means less money coming in from product sales, which can pressure BioNTech's cash available for research and capital spending. Analysts still expect a profit of 79 cents per share, so cost cuts or other income may be offsetting the weaker top line.

Analyst inference

The average analyst rating is buy, with 15 buy or strong buy calls, 8 holds and no sells. The median 12-month price target of $127.00 sits about 42.5% above the last closing price of $89.13, suggesting analysts see room for recovery despite falling revenue.

Analyst inference

What to watch

1. Watch whether reported revenue matches the mean estimate of €1.055 billion, a 30.6% decrease from €1.52 billion a year earlier, when results are released on November 3 for the quarter ending September 30, 2026. Confirmed
2. Watch whether earnings per share reach the 79 cents analysts expect; recent quarters show large misses and beats, so actual profit could differ widely from the mean estimate and shift investor views. Proposed
3. Watch for any comments on spending plans and cash needs, because lower revenue may force BioNTech to prioritise research projects or slow capital spending, which would affect future product revenue and investor positioning. Analyst inference

Evidence

• Original source link unavailable